Daniel Contreras on 31st Jul

Alzheimer’s LMTM drug failed to be beneficial for patients

Toronto – The 15-month trial drug, leuco-methylthioninium-bis (LMTM) failed to be significant for treating Alzheimer’s disease...

Read More
Daniel Contreras on 09th Jun

FDA Weighs Pros and Cons of Amgen’s High LDL Cholesterol Drug Repatha before approval

On Monday, the FDA released its review of a new Amgen cholesterol drug ahead of a meeting on Wednesday to consider the drug’s...

Read More